- Home
- ALLT vs DMAC Comparison
ALLT vs DMAC Comparison
Compare ALLT & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALLT
- DMAC
- Stock Information
- Founded
- ALLT 1996
- DMAC 2000
- Country
- ALLT Israel
- DMAC United States
- Employees
- ALLT N/A
- DMAC N/A
- Industry
- ALLT Telecommunications Equipment
- DMAC Biotechnology: Pharmaceutical Preparations
- Sector
- ALLT Telecommunications
- DMAC Health Care
- Exchange
- ALLT Nasdaq
- DMAC Nasdaq
- Market Cap
- ALLT 269.5M
- DMAC 224.6M
- IPO Year
- ALLT 2006
- DMAC N/A
- Fundamental
- Price
- ALLT $7.81
- DMAC $5.80
- Analyst Decision
- ALLT Buy
- DMAC Strong Buy
- Analyst Count
- ALLT 1
- DMAC 3
- Target Price
- ALLT $13.00
- DMAC $7.00
- AVG Volume (30 Days)
- ALLT 1.1M
- DMAC 100.7K
- Earning Date
- ALLT 02-25-2025
- DMAC 03-18-2025
- Dividend Yield
- ALLT N/A
- DMAC N/A
- EPS Growth
- ALLT N/A
- DMAC N/A
- EPS
- ALLT N/A
- DMAC N/A
- Revenue
- ALLT $91,631,000.00
- DMAC N/A
- Revenue This Year
- ALLT $0.41
- DMAC N/A
- Revenue Next Year
- ALLT $8.84
- DMAC N/A
- P/E Ratio
- ALLT N/A
- DMAC N/A
- Revenue Growth
- ALLT N/A
- DMAC N/A
- 52 Week Low
- ALLT $1.61
- DMAC $2.14
- 52 Week High
- ALLT $8.15
- DMAC $6.41
- Technical
- Relative Strength Index (RSI)
- ALLT 71.69
- DMAC 58.22
- Support Level
- ALLT $6.51
- DMAC $5.25
- Resistance Level
- ALLT $7.76
- DMAC $5.85
- Average True Range (ATR)
- ALLT 0.69
- DMAC 0.39
- MACD
- ALLT 0.05
- DMAC 0.01
- Stochastic Oscillator
- ALLT 86.03
- DMAC 73.02
About ALLT Allot Ltd.
Allot Ltd is a provider of network intelligence and security solutions for service providers and enterprises. The company's solutions are deployed globally for network and application analytics, traffic control and shaping, and network-based security services. The firm's multi-service platforms are deployed by mobile, fixed, and cloud service providers and enterprises. It has a customer base in Europe, Asia and Oceania, the Americas, the Middle East, and Africa.
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is principally engaged in the business activity of developing treatments for unmet clinical needs or where no therapies are available with a primary focus on chronic kidney disease and acute ischemicstroke. Its pipeline product DM199 is a recombinant form of human tissue kallikrein-1.